The effect of curcumin (Curcuma longa L.) on circulating levels of adiponectin in patients with metabolic syndrome

Malihe Moammeri Salahshooh; Seyed Mahammad Raza Parizadeh; Alireza Pasdar; Maryam Saberi Karimian; Hamide Safarian; Ali Javandoost; Gordon A. Ferns; Majid Ghayour-Mobarhan; Amirhosein Sahebkar

doi:10.1007/s00580-016-2339-5

The effect of curcumin (Curcuma longa L.) on circulating levels of adiponectin in patients with metabolic syndrome

Malihe Moammeri Salahshooh, Seyed Mahammad Raza Parizadeh, Alireza Pasdar, Maryam Saberi Karimian, Hamide Safarian, Ali Javandoost, Gordon A. Ferns, Majid Ghayour-Mobarhan^*, Amirhosein Sahebkar

^*Corresponding author for this work

Applied Medicine

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

In modern societies, metabolic syndrome (MetS) is a highly common disease, which is closely associated with the increased risk of cardiovascular disease (CVD). Metabolic syndrome is usually accompanied by low levels of adiponectin, which is a key regulator of insulin sensitivity and reduced inflammation of the tissue. Adiponectin also reduces systemic insulin resistance and predicts cardiovascular disease. Curcumin has several beneficial effects on risk factors of metabolic syndrome. This polyphenol can affect almost all components of metabolic syndrome including insulin resistance, hypertension and obesity. According to the low oral bioavailability of curcumin, several phospholipid-complex formulations have been developed to address this issue. The present study aims to evaluate the impact of unformulated curcumin and a phospholipid complex of curcumin on serum adiponectin in subjects with metabolic syndrome. Subjects (n = 120) with metabolic syndrome were randomly assigned to three groups which received capsules of phospholipidated curcumin (1 g/day), (n = 40), unformulated curcumin (n = 40) and placebo (n = 40) for a period of 6 weeks. The serum concentrations of adiponectin were measured at baseline and at the end of study using ELISA. The results showed a significant elevation of serum adiponectin concentrations in the curcumin group (mean change 28.9 ± 30.5) in comparison to both curcumin-phospholipid complex (mean change 4.1 ± 15.4) and placebo (mean change −3.5 ± 20.4) groups. Curcumin supplementation increased serum adiponectin concentrations, but this effect was not caused by phospholipid-curcumin complex.

Original language	English
Pages (from-to)	17-23
Number of pages	7
Journal	Comparative Clinical Pathology
Volume	26
Early online date	7 Oct 2016
DOIs	https://doi.org/10.1007/s00580-016-2339-5
Publication status	Published - 1 Jan 2017

Bibliographical note

We frankly thank all the patients and their family members who volunteered to participate in this study. Also, the authors would like to thank Mashhad University of Medical Sciences (MUMS) for financial support. The authors are also thankful to Indena S.p.A for providing curcumin supplements. The results presented in this work are part of Mrs. Malihe Moammeri Salahshooh’s thesis in MUMS.

This work was supported by Mashhad University of Medical Science (MUMS), Iran.

Keywords

Adiponectin
Curcumin
Metabolic syndrome
Phospholipid complex of curcumin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00580-016-2339-5Licence: Unspecified

Cite this

@article{af0abec2c1f4434a93543d0f2c310edb,

title = "The effect of curcumin (Curcuma longa L.) on circulating levels of adiponectin in patients with metabolic syndrome",

abstract = "In modern societies, metabolic syndrome (MetS) is a highly common disease, which is closely associated with the increased risk of cardiovascular disease (CVD). Metabolic syndrome is usually accompanied by low levels of adiponectin, which is a key regulator of insulin sensitivity and reduced inflammation of the tissue. Adiponectin also reduces systemic insulin resistance and predicts cardiovascular disease. Curcumin has several beneficial effects on risk factors of metabolic syndrome. This polyphenol can affect almost all components of metabolic syndrome including insulin resistance, hypertension and obesity. According to the low oral bioavailability of curcumin, several phospholipid-complex formulations have been developed to address this issue. The present study aims to evaluate the impact of unformulated curcumin and a phospholipid complex of curcumin on serum adiponectin in subjects with metabolic syndrome. Subjects (n = 120) with metabolic syndrome were randomly assigned to three groups which received capsules of phospholipidated curcumin (1 g/day), (n = 40), unformulated curcumin (n = 40) and placebo (n = 40) for a period of 6 weeks. The serum concentrations of adiponectin were measured at baseline and at the end of study using ELISA. The results showed a significant elevation of serum adiponectin concentrations in the curcumin group (mean change 28.9 ± 30.5) in comparison to both curcumin-phospholipid complex (mean change 4.1 ± 15.4) and placebo (mean change −3.5 ± 20.4) groups. Curcumin supplementation increased serum adiponectin concentrations, but this effect was not caused by phospholipid-curcumin complex.",

keywords = "Adiponectin, Curcumin, Metabolic syndrome, Phospholipid complex of curcumin",

author = "Salahshooh, {Malihe Moammeri} and Parizadeh, {Seyed Mahammad Raza} and Alireza Pasdar and {Saberi Karimian}, Maryam and Hamide Safarian and Ali Javandoost and Ferns, {Gordon A.} and Majid Ghayour-Mobarhan and Amirhosein Sahebkar",

note = "We frankly thank all the patients and their family members who volunteered to participate in this study. Also, the authors would like to thank Mashhad University of Medical Sciences (MUMS) for financial support. The authors are also thankful to Indena S.p.A for providing curcumin supplements. The results presented in this work are part of Mrs. Malihe Moammeri Salahshooh{\textquoteright}s thesis in MUMS. This work was supported by Mashhad University of Medical Science (MUMS), Iran.",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/s00580-016-2339-5",

language = "English",

volume = "26",

pages = "17--23",

journal = "Comparative Clinical Pathology",

issn = "1618-5641",

publisher = "Springer London",

}

TY - JOUR

T1 - The effect of curcumin (Curcuma longa L.) on circulating levels of adiponectin in patients with metabolic syndrome

AU - Salahshooh, Malihe Moammeri

AU - Parizadeh, Seyed Mahammad Raza

AU - Pasdar, Alireza

AU - Saberi Karimian, Maryam

AU - Safarian, Hamide

AU - Javandoost, Ali

AU - Ferns, Gordon A.

AU - Ghayour-Mobarhan, Majid

AU - Sahebkar, Amirhosein

N1 - We frankly thank all the patients and their family members who volunteered to participate in this study. Also, the authors would like to thank Mashhad University of Medical Sciences (MUMS) for financial support. The authors are also thankful to Indena S.p.A for providing curcumin supplements. The results presented in this work are part of Mrs. Malihe Moammeri Salahshooh’s thesis in MUMS. This work was supported by Mashhad University of Medical Science (MUMS), Iran.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In modern societies, metabolic syndrome (MetS) is a highly common disease, which is closely associated with the increased risk of cardiovascular disease (CVD). Metabolic syndrome is usually accompanied by low levels of adiponectin, which is a key regulator of insulin sensitivity and reduced inflammation of the tissue. Adiponectin also reduces systemic insulin resistance and predicts cardiovascular disease. Curcumin has several beneficial effects on risk factors of metabolic syndrome. This polyphenol can affect almost all components of metabolic syndrome including insulin resistance, hypertension and obesity. According to the low oral bioavailability of curcumin, several phospholipid-complex formulations have been developed to address this issue. The present study aims to evaluate the impact of unformulated curcumin and a phospholipid complex of curcumin on serum adiponectin in subjects with metabolic syndrome. Subjects (n = 120) with metabolic syndrome were randomly assigned to three groups which received capsules of phospholipidated curcumin (1 g/day), (n = 40), unformulated curcumin (n = 40) and placebo (n = 40) for a period of 6 weeks. The serum concentrations of adiponectin were measured at baseline and at the end of study using ELISA. The results showed a significant elevation of serum adiponectin concentrations in the curcumin group (mean change 28.9 ± 30.5) in comparison to both curcumin-phospholipid complex (mean change 4.1 ± 15.4) and placebo (mean change −3.5 ± 20.4) groups. Curcumin supplementation increased serum adiponectin concentrations, but this effect was not caused by phospholipid-curcumin complex.

AB - In modern societies, metabolic syndrome (MetS) is a highly common disease, which is closely associated with the increased risk of cardiovascular disease (CVD). Metabolic syndrome is usually accompanied by low levels of adiponectin, which is a key regulator of insulin sensitivity and reduced inflammation of the tissue. Adiponectin also reduces systemic insulin resistance and predicts cardiovascular disease. Curcumin has several beneficial effects on risk factors of metabolic syndrome. This polyphenol can affect almost all components of metabolic syndrome including insulin resistance, hypertension and obesity. According to the low oral bioavailability of curcumin, several phospholipid-complex formulations have been developed to address this issue. The present study aims to evaluate the impact of unformulated curcumin and a phospholipid complex of curcumin on serum adiponectin in subjects with metabolic syndrome. Subjects (n = 120) with metabolic syndrome were randomly assigned to three groups which received capsules of phospholipidated curcumin (1 g/day), (n = 40), unformulated curcumin (n = 40) and placebo (n = 40) for a period of 6 weeks. The serum concentrations of adiponectin were measured at baseline and at the end of study using ELISA. The results showed a significant elevation of serum adiponectin concentrations in the curcumin group (mean change 28.9 ± 30.5) in comparison to both curcumin-phospholipid complex (mean change 4.1 ± 15.4) and placebo (mean change −3.5 ± 20.4) groups. Curcumin supplementation increased serum adiponectin concentrations, but this effect was not caused by phospholipid-curcumin complex.

KW - Adiponectin

KW - Curcumin

KW - Metabolic syndrome

KW - Phospholipid complex of curcumin

UR - http://www.scopus.com/inward/record.url?scp=84990833541&partnerID=8YFLogxK

U2 - 10.1007/s00580-016-2339-5

DO - 10.1007/s00580-016-2339-5

M3 - Article

AN - SCOPUS:84990833541

SN - 1618-5641

VL - 26

SP - 17

EP - 23

JO - Comparative Clinical Pathology

JF - Comparative Clinical Pathology

ER -

The effect of curcumin (Curcuma longa L.) on circulating levels of adiponectin in patients with metabolic syndrome

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this